Covid 19 Research using Clinical Trials (Home Page)
RESP301, a Nitric Oxide generating solutionWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (3)
|
Name (Synonyms) |
Correlation |
drug2476 | Tested for SARS-CoV-2 (regardless of the result) Wiki | 1.00 |
drug583 | Clinical diagnosis of COVID-19 by a health care professional Wiki | 1.00 |
drug2319 | Standard of Care Wiki | 0.20 |
Correlated MeSH Terms (1)
|
Name (Synonyms) |
Correlation |
D018352 | Coronavirus Infections NIH | 0.04 |
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
The effect of RESP301 as an add on treatment to SOC will be evaluated for its efficacy in
reducing rate of progression to a more severe level of COVID-19 and for safety, by comparison
with SOC alone in hospitalized COVID-19 patients.
NCT04460183 COVID-19 Drug: RESP301, a Nitric Oxide generating solution Other: Standard of Care
Primary Outcomes
Measure: Proportion of participants who progress to level >4 of modified WHO ordinal scale due to COVID-19 by Day 14 Time: From Day 1 to Day 14
Secondary Outcomes
Measure: Change in room air oxygen saturation (SpO2) from baseline over time Time: Baseline to Day 28
Measure: Change in National Early Warning Score (NEWS) 2 symptom score from baseline over time Time: Baseline to Day 28
Measure: Change from baseline on the modified WHO ordinal scale at each visit up to Day 28 Time: Baseline to Day 28
Measure: Time to improvement to a lower level (<4) of modified WHO ordinal scale Time: Baseline to Day 28
Measure: Time to progression to a higher level (>4) of modified WHO ordinal scale Time: Baseline to Day 28
Measure: Number of participants with adverse events and serious adverse events Time: Baseline to Day 28
No related HPO nodes (Using clinical trials)